increased toxicities. Table 1 lists selected phase III trials for the first-line treatment of AGC. Commonly used regimens include docetaxel/cisplatin/5-fluorouracil (DCF); epirubicin/cisplatin/5-fluorouracil (ECF); epirubicin/oxaliplatin/5-fluorouracil
Search Results
Amit Mahipal, Minsig Choi, and Richard Kim
Emily Chan, Paul E. Wise, and A. Bapsi Chakravarthy
-inferiority end point. Therefore, capecitabine could replace FU in adjuvant or neoadjuvant chemoradiation regimens. 27 NSABP R-04 compared the use of capecitabine with continuous-infusion 5-FU (both with and without oxaliplatin), and both have been equivalent in
Margaret A. Tempero, Mokenge P. Malafa, Mahmoud Al-Hawary, Horacio Asbun, Andrew Bain, Stephen W. Behrman, Al B. Benson III, Ellen Binder, Dana B. Cardin, Charles Cha, E. Gabriela Chiorean, Vincent Chung, Brian Czito, Mary Dillhoff, Efrat Dotan, Cristina R. Ferrone, Jeffrey Hardacre, William G. Hawkins, Joseph Herman, Andrew H. Ko, Srinadh Komanduri, Albert Koong, Noelle LoConte, Andrew M. Lowy, Cassadie Moravek, Eric K. Nakakura, Eileen M. O'Reilly, Jorge Obando, Sushanth Reddy, Courtney Scaife, Sarah Thayer, Colin D. Weekes, Robert A. Wolff, Brian M. Wolpin, Jennifer Burns, and Susan Darlow
-based regimens (eg, GEMOX [gemcitabine/oxaliplatin]; GTX [gemcitabine/docetaxel/capecitabine]) (see “Gemcitabine Combinations,” next section). 47 , 48 Gemcitabine Combinations Because gemcitabine is superior to bolus 5-FU in the advanced setting when the
Amy Zhou, Manik Amin, Kathryn J. Fowler, Elizabeth M. Brunt, Jesse Keller, and Benjamin Tan
could be made regarding the correlation of EGFR expression to disease response given the small sample size. 33 Subsequently, a phase III randomized controlled trial with gemcitabine and oxaliplatin with or without erlotinib was conducted, which
Mohamedtaki A. Tejani, Anna ter Veer, Dana Milne, Rebecca Ottesen, Tanios Bekaii-Saab, Al B. Benson III, Deborah Schrag, Stephen Shibata, John Skibber, Martin Weiser, Neal Wilkinson, and Steven J. Cohen
provided in Table 2 . The most common combination was a fluoropyrimidine plus oxaliplatin with or without bevacizumab (37% and 33%, respectively). The remaining patients either received fluoropyrimidine/irinotecan or single-agent fluoropyrimidine
Margaret A. Tempero, Mokenge P. Malafa, Mahmoud Al-Hawary, Stephen W. Behrman, Al B. Benson III, Dana B. Cardin, E. Gabriela Chiorean, Vincent Chung, Brian Czito, Marco Del Chiaro, Mary Dillhoff, Timothy R. Donahue, Efrat Dotan, Cristina R. Ferrone, Christos Fountzilas, Jeffrey Hardacre, William G. Hawkins, Kelsey Klute, Andrew H. Ko, John W. Kunstman, Noelle LoConte, Andrew M. Lowy, Cassadie Moravek, Eric K. Nakakura, Amol K. Narang, Jorge Obando, Patricio M. Polanco, Sushanth Reddy, Marsha Reyngold, Courtney Scaife, Jeanne Shen, Charles Vollmer Jr., Robert A. Wolff, Brian M. Wolpin, Beth Lynn, and Giby V. George
results of an open phase I study to assess the feasibility of a combination therapy consisting of 5-FU/leucovorin plus oxaliplatin and irinotecan (FOLFIRINOX) for the treatment of patients with metastatic solid tumors. 116 Their study included 2 patients
Daenielle Lang and Kristen K. Ciombor
as doublet or triplet therapy, such as folinic acid/5-FU/oxaliplatin (FOLFOX), folinic acid/5-FU/irinotecan (FOLFIRI), capecitabine/oxaliplatin (CAPOX), or folinic acid/5-FU/oxaliplatin/irinotecan (FOLFIRINOX). 21 Addition of anti-VEGF therapy (ie
F. Anthony Greco
Sargent DJ Morton RF . A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer . J Clin Oncol 2004 ; 22 : 23 – 30 . 7
Diane Reidy and Leonard Saltz
. 3. Punt CJ Koopman M Douma J . Sequential compared to combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC): a Dutch Colorectal Cancer Group (DCCG) phase III study [abstract] . J Clin Oncol
Jaffer A. Ajani, James S. Barthel, Tanios Bekaii-Saab, David J. Bentrem, Thomas A. D'Amico, Prajnan Das, Crystal Denlinger, Charles S. Fuchs, Hans Gerdes, James A. Hayman, Lisa Hazard, Wayne L. Hofstetter, David H. Ilson, Rajesh N. Keswani, Lawrence R. Kleinberg, Michael Korn, Kenneth Meredith, Mary F. Mulcahy, Mark B. Orringer, Raymond U. Osarogiagbon, James A. Posey, Aaron R. Sasson, Walter J. Scott, Stephen Shibata, Vivian E. M. Strong, Mary Kay Washington, Christopher Willett, Douglas E. Wood, Cameron D. Wright, and Gary Yang
etoposide, oxaliplatin, and UFT (a combination of uracil and tegafur), have shown activity as single agents and in combination in patients with advanced gastric cancer. 87 – 98 Irinotecan as a single agent or in combination has been explored extensively in
